Clinical Trial Update: Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis [Phase 4]

View source ↗

Summary

Phase 4 trial assessing whether infliximab induces histologic and endoscopic remission in moderate to severe ulcerative colitis; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Grupo de Estudo da Doença Inflamatória Intestinal | Conditions: Ulcerative Colitis | Phase 4 | Status: COMPLETED